Evolution of the cardiometabolic profile of primary hyperaldosteronism patients treated with adrenalectomy and with mineralocorticoid receptor antagonists: results from the SPAIN-ALDO Registry-Reference-Cited by-同舟云学术

Evolution of the cardiometabolic profile of primary hyperaldosteronism patients treated with adrenalectomy and with mineralocorticoid receptor antagonists: results from the SPAIN-ALDO Registry

Published:2022-03-11 Issue:3 Volume:76 Page:687-696
ISSN:1559-0100
Container-title:Endocrine
language:en
Short-container-title:Endocrine

Author:

Araujo-Castro Marta^ORCID,Paja Fano Miguel,González Boillos Marga,Pla Peris Begoña,Pascual-Corrales Eider,García Cano Ana María,Parra Ramírez Paola,Rojas-Marcos Patricia Martín,Ruiz-Sanchez Jorge Gabriel,Vicente Delgado Almudena,Gómez Hoyos Emilia,Ferreira Rui,García Sanz Iñigo,Díaz Guardiola Patricia,García González Juan Jesús,Perdomo Carolina M.,Morales Manuel,Hanzu Felicia A.

Funder

Fundación SEEN

Publisher

Springer Science and Business Media LLC

Subject

Endocrinology,Endocrinology, Diabetes and Metabolism

Link

https://link.springer.com/content/pdf/10.1007/s12020-022-03029-4.pdf

Reference43 articles.

1. G.P. Rossi, G. Bernini, C. Caliumi, G. Desideri, B. Fabris, C. Ferri et al. A prospective study of the prevalence of primary aldosteronism in 1,125 hypertensive patients. J. Am. Coll. Cardiol. 48, 2293–2300 (2006) https://doi.org/10.1016/j.jacc.2006.07.059

2. P. Milliez, X. Girerd, P.F. Plouin, J. Blacher, M.E. Safar, J.J. Mourad et al. Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism. J. Am. Coll. Cardiol. 45, 1243–1248 (2005) https://doi.org/10.1016/j.jacc.2005.01.015

3. G.P. Rossi, G. Bernini, G. Desideri, B. Fabris, C. Ferri, G. Giacchetti et al. Renal damage in primary aldosteronism: results of the PAPY study. Hypertension 48, 232–238 (2006) https://doi.org/10.1161/01.HYP.0000230444.01215.6a